← Back to Search

Topical Anesthetics for Lentigo

N/A
Waitlist Available
Led By Murad Alam, MD
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day of treatment

Summary

This trial will compare how well 3 different topical anesthetics work on patients' pain during treatment for lentigines (age/liver spots) and/or photorejuvenation ( improving skin appearance).

Who is the study for?
This trial is for women aged 25-65 with skin types I-III who have moderate lentigines or photodamage and want laser treatment. They must be in good health, able to consent, and not pregnant. Exclusions include certain medical conditions, recent facial treatments, allergies to anesthetics, chronic pain conditions, liver/kidney disease, or tanned skin.
What is being tested?
The study tests how well different topical anesthetics reduce pain during Q-switched laser treatment for lentigo. It compares lidocaine/prilocaine (LPTA), lidocaine/tetracaine (LTTA), and a placebo. Patients' pain levels are measured after each treated area using a visual scale.
What are the potential side effects?
Possible side effects of the topical anesthetics may include temporary redness, swelling at the application site, itching or tingling sensations. There's also a risk of allergic reactions for those sensitive to lidocaine, tetracaine or prilocaine.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and day of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
visual analog score (VAS) pain rating

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: lidocaine 2.5%/prilocaine 2.5% topical anestheticActive Control2 Interventions
Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
Group II: lidocaine 7%/tetracaine 7% topical anestheticActive Control2 Interventions
Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.
Group III: placebo vehiclePlacebo Group2 Interventions
Subjects will be screened, assessed, and randomized to be treated with a single pass of the Q-switched 532nm laser after application of LPTA, LTTA, or PV under occlusion to the assigned randomized site.

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,640 Previous Clinical Trials
957,524 Total Patients Enrolled
Murad Alam, MDPrincipal InvestigatorNorthwestern University
69 Previous Clinical Trials
2,532 Total Patients Enrolled

Media Library

lidocaine 2.5%/prilocaine 2.5% topical anesthetic Clinical Trial Eligibility Overview. Trial Name: NCT02427724 — N/A
Freckles Research Study Groups: lidocaine 2.5%/prilocaine 2.5% topical anesthetic, lidocaine 7%/tetracaine 7% topical anesthetic, placebo vehicle
Freckles Clinical Trial 2023: lidocaine 2.5%/prilocaine 2.5% topical anesthetic Highlights & Side Effects. Trial Name: NCT02427724 — N/A
lidocaine 2.5%/prilocaine 2.5% topical anesthetic 2023 Treatment Timeline for Medical Study. Trial Name: NCT02427724 — N/A
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top